Safety and efficacy of bimekizumab through 2 years in patients with moderate-To-severe plaque psoriasis: Longer-Term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

Diamant Thaçi*, Ron Vender, Menno A. De Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball

*Corresponding author for this work
6 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of bimekizumab through 2 years in patients with moderate-To-severe plaque psoriasis: Longer-Term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry